New research has revealed that many sickle cell disease patients in the United States are not receiving a potentially effective treatment called a red blood cell exchange, even though most hospitals have access to the technology. This procedure involves removing a patient’s damaged red blood cells and replacing them with healthy donor cells, while preserving the patient’s plasma, platelets, and white blood cells. A recent survey of 100 U.S. healthcare providers who manage sickle cell patients found that fewer than 3% of patients had received this treatment, despite 91% of providers reporting they have access to it. The study highlights several barriers, including difficulties in coordination between medical departments, a shortage of donated blood, and a general lack of familiarity with the procedure. Only 5% of providers reported no obstacles in delivering the treatment. Sickle cell disease, also known as sickle cell anemia, is a genetic condition that affects hemoglobin, the protein in red blood cells that carries oxygen. In healthy individuals, red blood cells are disc-shaped and flexible, allowing them to move easily through blood vessels. In people with sickle cell disease, the cells become crescent-shaped, making them rigid and prone to blocking blood flow. This can lead to pain, organ damage, and other serious complications. The disease primarily affects people of color, with over 100,000 cases in the U.S. and 8 million globally. About 90% of those diagnosed are non-Hispanic Black or African American, and 3% to 9% are Hispanic or Latino. Dr. Aaron Haubner, lead author of the research and a professor at the University of Kentucky College of Pharmacy, emphasized that while new treatments for sickle cell disease are promising, they remain largely inaccessible to most patients. He noted that effective treatment requires a coordinated team of specialists, including hematologists, transfusion experts, and care coordinators. However, these resources are often concentrated in specialized centers, leaving many communities without adequate access. Haubner suggested that expanding the number of comprehensive sickle cell disease centers across the country could improve treatment availability and long-term care for patients. Dr. Edward Donnell Ivy, chief medical officer at the Sickle Cell Disease Association of America, highlighted that patients themselves can play a role in addressing barriers to care by asking about available treatments. He also pointed out that many sickle cell patients rely on Medicaid and face socioeconomic challenges, which can further limit their access to care. Geography is another factor, as many patients live in rural areas with limited access to specialized equipment and treatment options. Dr. Shannon Kelly, medical director of the apheresis program at UCSF Benioff Children’s Hospital Oakland, noted that her hospital often receives patients from other centers that lack the necessary infrastructure for red blood cell exchange. She emphasized the difficulty of maintaining such specialized care in areas with small patient populations, particularly in rural regions.